Virtual NanoSight User Meeting

In this user meeting, NanoSight experts from Malvern Panalytical will discuss best practices, what’s new in the world of NTA, factors to consider when measuring non-spherical particles, and considerations when validating particle concentration measurements. Additionally, two NanoSight users will present their results in the fields of exosome research and lipid nanoparticles for gene therapy. The meeting will conclude with an open Q+A session, where NanoSight users will be able to ask NTA experts questions.


Carla Mazzeo, M.Sc., Ph.D.

Carla Mazzeo obtained her Ph.D. from the Autonomous University of Madrid (UAM). Her doctoral thesis was dedicated to the biogenesis of exosomes in the immune system. In 2015, she has published the first characterization of eosinophils exosomes and their important role in asthma. At the Institute of Molecular Biology "Severo Ochoa" -UAM, Carla has studied a new strategy to block the secretion of exosomes that cause metastasis in melanoma . In 2018, Carla began working as a Research Scientist at Boston University, studying mechanisms of myelofibrosis and in December 2020, Carla joins the Moss Lab to study exosomes as a non-invasive method of diagnosis and treatment for inflammatory bowel diseases (IBD) and the implication of exosomes in the development of Crohn Disease. Carla is creating a training program at Boston University School of Medicine (BUSM) dedicated to the education, training and study of EVs. She was awarded as the BUSM Distinguished Staff in 2020.

Teresa McDonald

Teresa is currently a Principal Research Associate at Beam Therapeutics in the Analytical Development group. She learned NTA at Codiak Biosciences where she developed and qualified an NTA method for exosomes, which was transferred to multiple CMOs across the country. At Beam Therapeutics, she developed an NTA method for assessing the size distribution of lipid nanoparticles. She received her master’s degree in Chemistry at the University of Oregon in 2015. She currently resides in Boston, Massachusetts.

Jonathan Mehtala Ph.D.

Jonathan studied Chemistry at the University of Massachusetts Amherst, and joined the Field Application Scientist team at MalvernPanalytical in 2014 after completing his Ph.D. in Chemistry at Purdue University. During his doctoral studies at Purdue, he developed gold nanorod hyperthermia systems for cancer therapy and self-assembled protein nanoparticles for drug delivery. At MalvernPanalytical, Jonathan worked primarily with the Zetasizer and NanoSight product lines in multiple application spaces, from gene therapy, therapeutic proteins, extracellular vesicles, and drug delivery. Over the last six years, Jonathan has been involved in various forms of AAV characterization. From original research in developing novel gold nanoparticle labelling methods to increase the scattering signal of AAV particles, to understanding the strengths and weaknesses of orthogonal analytical assays to measure AAV titer.

Arianna Biesso, Ph.D.

Dr. Biesso received her Ph.D from the chemistry deparment at Georgia Tech under the supervision of Dr. Mustafa El-Sayed, working on nanoparticle and the interaction with photoactive proteins. After her Ph.D she received a fellowship from the National Institute of Health (NIH) working on ultrafast protein folding dynamics and single molecule fluorescence both at NHLBI and NIDDK.

After her fellowship at NIH she joined the R&D depatment of a company - Meso Scale Diagnostic- where she worked as a scientist in the development of supersensitive assays for diagnostic applications. She is currently at Malvern Panalytical, in the Pharma and Food division where she support NanoSight and other Malvern products.